Fosphenytoin

Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients

Retrieved on: 
Monday, November 9, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Anticonvulsants, Drugs, Hydantoins, Health, Branches of biology, Epilepsy, GABAA receptor positive allosteric modulators, Medical emergencies, Fosphenytoin, Status epilepticus, Seizure, Phenytoin, Sedor Pharmaceuticals, LLC, SESQUIENT

Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.

Key Points: 
  • Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.
  • Status epilepticus is associated with irreversible neurologic damage and death, both of which largely depend on the seizure duration before initial treatment, stated Barry Frankel, Chief Business Officer and co-founder of Sedor.
  • SESQUIENT the first and only FDA-approved room temperature stable fosphenytoin could help health care providers quickly treat status epilepticus patients and potentially reduce hospital costs associated with this condition.
  • The companys lead product, SESQUIENT, has received FDA approval for the treatment of status epilepticus.

Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients

Retrieved on: 
Friday, November 6, 2020
Health, FDA, Medical devices, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Anticonvulsants, Drugs, Hydantoins, Health, Branches of biology, Epilepsy, Fosphenytoin, Prodrugs, Medical emergencies, Status epilepticus, Phenytoin, Food and Drug Administration, SESQUIENT, Captisol®, Sedor Pharmaceuticals, LLC, Ligand

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration (FDA) for SESQUIENT, a Captisol-enabled Fosphenytoin (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration (FDA) for SESQUIENT, a Captisol-enabled Fosphenytoin (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.
  • We are pleased to see Sedors progress with SESQUIENT and todays FDA approval for another Captisol-based medicine, said John Higgins, CEO Ligand Pharmaceuticals.
  • Like many other drugs, Captisol plays an important role in the formulation of this drug for IV administration to patients undergoing status epilepticus seizures.
  • The companys lead product, SESQUIENT, has received FDA approval for the treatment of status epilepticus.